Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue

References

• Renqvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001; 50: 3–15
   PubMedGoogle Scholar
• Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23: 2346–57
   PubMed Web of Science ®Google Scholar
• Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126–9
   PubMed Web of Science ®Google Scholar
• Tuettenberg A, Becker C, Huter E, Knop J, Enk AH, Jonuleit H. Induction of strong and persistent Melan A/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients. Int J Cancer 2006; 118: 2617–27
   PubMed Web of Science ®Google Scholar
• Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24: 3089–94
   PubMed Web of Science ®Google Scholar
• Stift A, Sachet M, Yagubian R, Bittermann C, Dubsky P, Brostjan C, et al. Dendritic cell vaccination in medullary thyroid carcinoma. Clin Cancer Res 2004; 10: 2944–53
   PubMed Web of Science ®Google Scholar
• Ferrantini M, Capone I, Marincola FM, Parmiani G, Belardelli F. International meeting “Immunotherapy of cancer: Challenges and needs”. Cancer Immunol Immunother 2007; 56: 581–5
   PubMedGoogle Scholar
• Zou W. Immunosuppressive networks in the tumor environment and their therapeutic relevance. Nature Rev Cancer 2005; 5: 263–74
   PubMed Web of Science ®Google Scholar
• Zou W. Regulatory T cells, tumor immunity and immunotherapy. Nat Rev Immunol 2006; 6: 295–307
   PubMed Web of Science ®Google Scholar
• Wilczynski JR, Radwan M, Kalinka J. The characterization and role of regulatory T cells in immune reactions. Front Biosci 2008; 13: 2266–74
   PubMed Web of Science ®Google Scholar
• Jonuleit H, Schmitt E. The regulatory T cell family: Distinct subsets and their interrelations. J Immunol 2003; 171: 6323–7
   PubMed Web of Science ®Google Scholar
• Liu W, Putnam AL, Xu-yu Z, Szot GL, Lee MR, Zhu S, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ Treg cells. J Exp Med 2006; 203: 1701–11
   PubMed Web of Science ®Google Scholar
• Hartigan-O′Connor DJ, Poon C, Sinclair E, McCune JM. Human CD4+ regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells. J Immunol Method 2007; 319: 41–52
   PubMed Web of Science ®Google Scholar
• Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001; 61: 4766–72
   PubMed Web of Science ®Google Scholar
• Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169: 2756–61
   PubMed Web of Science ®Google Scholar
• Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies. Cancer 2003; 98: 1089–99
   PubMed Web of Science ®Google Scholar
• Miller AM, Lundberg K, Özenci V, Banham AH, Hellström M, Egevad L, et al. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006; 177: 7398–405
   PubMed Web of Science ®Google Scholar
• Loskog A, Ninalga C, Paul-Wetterberg G, de la Torre M, Malmström P-U, Tötterman TH. Human bladder carcinoma is dominated by T regulatory cells and Th1 inhibitory cytokines. J Urol 2007; 177: 353–8
   PubMed Web of Science ®Google Scholar
• Papewalis C, Wuttke M, Jacobs B, Domberg J, Willenberg H, Baehring T, et al. Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma. Horm Metab Res 2008; 40: 108–16
   PubMedGoogle Scholar
• Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942–9
   PubMed Web of Science ®Google Scholar
• Petersen RP, Carpa MJ, Sperlazza J, Conlon D, Joshi MB, Harpole DH, Jr, et al. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006; 107: 2866–72
   PubMed Web of Science ®Google Scholar
• Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006; 24: 5373–80
   PubMed Web of Science ®Google Scholar
• Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T, et al. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 2007; 13: 902–11
   PubMed Web of Science ®Google Scholar
• Badoual C, Hans S, Rodriguez J, Peyrard S, Klein C, Agueznay Nel H, et al. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 2006; 12: 465–72
   PubMed Web of Science ®Google Scholar
• Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I/II study. Ann Surg Oncol 2005; 12: 1005–16
   PubMed Web of Science ®Google Scholar
• Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003; 100: 8372–7
   PubMed Web of Science ®Google Scholar
• Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 2003; 100: 4712–7
   PubMed Web of Science ®Google Scholar
• Berd D, Mastrangelo MJ. Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+ 2H4+ suppressor-inducer T cells. Cancer Res 1988; 48: 1671–5
   PubMed Web of Science ®Google Scholar
• Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 115: 3623–33
   PubMed Web of Science ®Google Scholar
• Åkerström G, Hellman P, Hessman O, Osmak L. Management of midgut carcinoids. J Surg Oncol 2005; 89: 161–9
   PubMedGoogle Scholar
• Van der Horst-Schrivers ANA, Machteld Wymenga AN, Links TP, Willemse PHB, Kema IP, de Vries EGE. Complications of midgut carcinoid tumors and carcinoid syndrome. Neuroendocrinology 2004; 80(Suppl 1)28–32
   PubMedGoogle Scholar
• Öberg K. Neuroendocrine tumors of the gastrointestinal tract: Recent advances in molecular genetics, diagnosis, and treatment. Curr Opin Oncol 2005; 17: 386–91
   PubMed Web of Science ®Google Scholar
• Schott M, Seissler J. Dendritic cell vaccination: New hope for the treatment of metastasized endocrine malignancies. Trends Endocrinol Metab 2003; 14: 156–62
   PubMed Web of Science ®Google Scholar
• Vikman S, Essand M, Cunningham JL, de la Torre M, Öberg K, Tötterman TH, et al. Gene expression in midgut carcinoid tumors: potential targets for immunotherapy. Acta Oncol 2005; 44: 32–40
   PubMed Web of Science ®Google Scholar
• Vikman S, Giandomenico V, Sommaggio R, Öberg K, Essand M, Tötterman TH. CD8+ T cells against multiple tumor-associated antigens in peripheral blood of midgut carcinoid patients. Cancer Immunol Immunother 2008; 57: 399–409
   PubMedGoogle Scholar
• Chen W, Perruche S, Li J. CD4+CD25+ T regulatory cells and TGF-beta in mucosal immune system: The good and the bad. Curr Med Chem 2007; 14: 2245–9
   PubMedGoogle Scholar
• Allez M, Mayer L. Regulatory T cells: Peace keepers in the gut. Inflamm Bowel Dis 2004; 10: 666–76
   PubMed Web of Science ®Google Scholar
• Weiner HL. The mucosal milieu creates tolerogenic dendritic cells and TR1 and TH3 regulatorycells. Nat Immunol 2001; 2: 671–2
   PubMedGoogle Scholar
• Zhang PJ, Furth EE, Cai X, Goldblum JR, Pascha TL, Min KW. The role of beta-catenin, TGF beta 3, NGF2, FGF2, IGFR2, and BMP4 in the pathogenesis of mesenteric sclerosis and angiopathy in midgut carcinoids. Hum Pathol 2004; 35: 670–4
   PubMedGoogle Scholar
• Wimmel A, Wiedenmann B, Rosewicz S. Autocrine growth inhibition by transforming growth factor β-1 (TGFβ-1) in human neuroendocrine tumor cells. Gut 2003; 52: 1308–16
   PubMedGoogle Scholar
• Zeutenhorst JM, Bonfrer JM, Korse CM, Bakker R, van Tinteren H, Taal BG. Carcinoid heart disease: The role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor. Cancer 2003; 97: 1609–15
   PubMedGoogle Scholar
• Chaudhry A, Funa K, Öberg K. Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system. Acta Oncol 1993; 32: 107–14
   PubMed Web of Science ®Google Scholar
• Beauchamp RD, Coffey RJ, Jr, Lyons RM, Perkett EA, Townsend CM, Jr, Moses HL. Human carcinoid cell production of paracrine growth factors that can stimulate fibroblast and endothelial cell growth. Cancer Res 1991; 51: 5253–60
   PubMed Web of Science ®Google Scholar
• Russo S, Boon JC, Kema IP, Willemse PH, den Boer JA, Korf J, et al. Patients with carcinoid syndrome exhibit symptoms of aggressive impulse dysregulation. Psychosom Med 2004; 66: 422–5
   PubMedGoogle Scholar
• Martinez A, Knappskog PM, Haavik J. A structural approach into human tryptophan hydroxylase and its implications for the regulation of serotonin biosynthesis. Curr Med Chem 2001; 8: 1077–91
   PubMed Web of Science ®Google Scholar
• Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007; 117: 1147–54
   PubMed Web of Science ®Google Scholar
• Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor ξ-chain and induce a regulatory phenotype in naïve T cells. J Immunol 2006; 176: 6752–61
   PubMed Web of Science ®Google Scholar